Is BPC-157 legal in the US?
No — BPC-157 is not an FDA-approved drug, and it is not currently legal to compound either. In April 2026 the FDA removed it from Category 2 (because the nominations were withdrawn), but did not move it to the approved Category 1 list, leaving it in a regulatory gray zone. The committee votes on July 23, 2026.
Approved vs compoundable vs “research-use” — the distinction that matters
An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 BPC-157 was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.
What happens on July 23
The FDA’s Pharmacy Compounding Advisory Committee will hear evidence and vote on whether BPC-157 should be added to the 503A list for ulcerative colitis. A “yes” is a recommendation only; the FDA would then need to issue a final rule before any pharmacy could legally compound it. Realistic patient access, if it happens at all, is late 2026 to early 2027.
Will BPC-157 become legal in 2026?+
Is “research-grade” BPC-157 the same as a medicine?+
Primary sources: 2025 review: PMID 40756949 · trials: ClinicalTrials.gov NCT07437547, NCT02637284 · FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. BPC-157 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.